Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study
Jacksonville, Fla., Rochester, Minn.
Open for Enrollment
Why is this study being done?
This study will investigate the effects of the combination of bosentan and sildenafil. Patients with symptomatic PAH treated with a stable dose of sildenafil equal to or greater tha 20 mg t.i.d. for at least 12 weeks will be randomized to placebo or bosentan 125 mg b.i.d. All randomized patients will be treated with study drug until the predefined target number of morbidity/mortality events is reached.
Who can I contact for additional information about this study?
Rochester: Karen Swanson, MD 507-284-1838
Louise Durst 507-284-1838
Jacksonville: Charles Burger, MD 904-953-2381
Pamela Long 904-953-7719